Supreme Court Issues Mixed Ruling on Biotech-Drug Copies

Source: Bloomberg

Tuesday, June 13, 2017 | Health Care

The U.S. Supreme Court issued a mixed decision on the rules governing efforts to get low-cost alternatives to pricey biotechnology drugs on the market. The justices said patent holders can’t use federal law to enforce a requirement that companies seeking to sell “biosimilars” provide information about their product. The unanimous court, however, said patent holders might be able to use state law to accomplish the same goal.

Open in New Window


You must be logged in to leave a comment.